Casdin Capital Portfolio

Casdin Capital 13F filer (CIK 0001534261).

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q4 2019 · 32 positions · Total reported value $1.09B · Top-10 concentration 62.3% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 26.1% · 6 new · 3 cut · 3 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 99.9% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +47.2% · vs SPY +32.4% · Prev Value $1.32B — last quarter positions weighted by this quarter price moves · ranking

In its Q4 2019 13F filing, Casdin Capital disclosed 32 equity positions with a combined reported value of $1.09B. The filing implies a focused portfolio: its ten largest positions account for 62.3% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2019 were SRPT ($86.46M), BLUE ($85.12M), CDXS ($81.13M). By sector, the heaviest allocations are Health Care 44.6%, Industrials 7.5%. Versus the prior quarter, allocation shifted toward Health Care (+6.3pp) and away from Other (-6.6pp).

Versus the prior quarter, Casdin Capital opened 6 new positions, trimmed 3 and fully exited 3, a turnover rate of 26.1% of positions. The portfolio's overlap with the prior quarter was 86% of names.

The largest new positions opened in Q4 2019 were GILD ($13.00M), BMYRT ($4.51M).

Of the 3 positions fully exited versus the prior quarter, the largest were ONCE ($83.72B), FIXX ($14.84B), EDIT ($9.44B).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2019)

  • GILD GILEAD SCIENCES INC · $13.00M
  • BMYRT BRISTOL-MYERS SQUIBB CO · $4.51M

Fully Exited (vs previous quarter)

  • ONCE SPARK THERAPEUTICS INC · prev qtr: $83.72B
  • FIXX HOMOLOGY MEDICINES INC · prev qtr: $14.84B
  • EDIT EDITAS MEDICINE INC · prev qtr: $9.44B · history

Insider Transactions (Form 4)

Latest Casdin Capital buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Casdin Capital is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 43 US equity positions with a combined value of $2.00B. HoldingsHub carries 43 quarters of its filings (Q4 2015–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-110894 (status: Approved), registered 2017-07-31
  • Regulatory AUM (Form ADV): $2.87B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 5 private funds, of which 2 hedge funds

Portfolio Structure

  • 43 positions · $2.00B reported value (Q2 2026)
  • Top 10 holdings = 77.4% of reported value
  • Largest position: RVMD (REVOLUTION MEDICINES INC) at 24.2%
  • Average position size: $46.46M

Sector Tilt

  • Health Care 94.2%
  • Industrials 5.7%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 9 added, 3 reduced, 3 exited
  • 25 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 44.6%
Other 47.9%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 670.00K $86.46M 7.95%
7.95%
Reduce
2 970.00K $85.12M 7.83%
7.83%
Add
3 5.07M $81.13M 7.46%
7.46%
Hold
4 940.00K $75.30M 6.92%
6.92%
Hold
5 1.00M $73.25M 6.74%
6.74%
Reduce
6 515.00K $59.31M 5.45%
5.45%
Reduce
7 3.64M $58.69M 5.40%
5.40%
Reduce
8 1.21M $57.13M 5.25%
5.25%
Reduce
9 860.00K $51.46M 4.73%
4.73%
Hold
10 2.55M $49.90M 4.59%
4.59%
Hold
11 3.10M $46.97M 4.32%
4.32%
Add
12 2.47M $39.94M 3.67%
3.67%
Add
13 825.00K $39.39M 3.62%
3.62%
Reduce
14 1.20M $25.88M 2.38%
2.38%
Add
15 300.00K $23.85M 2.19%
2.19%
Hold
16 1.25M $21.77M 2.00%
2.00%
Add
17 1.24M $20.62M 1.90%
1.90%
Add
18 60.00K $19.90M 1.83%
1.83%
Hold
19 2.16M $19.38M 1.78%
1.78%
Add
20 1.08M $18.54M 1.71%
1.71%
Add
21 230.00K $16.60M 1.53%
1.53%
Reduce
22 3.37M $16.19M 1.49%
1.49%
Hold
23 255.00K $15.87M 1.46%
1.46%
Add
24 1.10M $15.28M 1.41%
1.41%
Reduce
25 463.12K $13.86M 1.27%
1.27%
Hold
26 200.00K $13.00M 1.20%
1.20%
New
27 1.46M $12.18M 1.12%
1.12%
Hold
28 820.00K $11.28M 1.04%
1.04%
Add
29 300.00K $6.30M 0.58%
0.58%
Hold
30 75.00K $4.67M 0.43%
0.43%
Hold
31 1.50M $4.51M 0.41%
0.41%
New
32 130.00K $3.68M 0.34%
0.34%
Hold

FAQ

What did Casdin Capital buy in 2019-Q4?

In its 2019-Q4 13F filing, Casdin Capital reported 32 equity positions worth $1.09B in aggregate; its largest disclosed positions were SRPT ($86.46M), BLUE ($85.12M), CDXS ($81.13M).

How large is Casdin Capital's portfolio?

Casdin Capital reported $1.09B of long equity holdings across 32 positions as of 2019-Q4. Top-10 holdings account for 62.3% of reported value.

What is Casdin Capital's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/casdin/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →